GO:0035499 carnosine biosynthetic process: Dipeptide Synthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035499 carnosine biosynthetic process describes the biochemical reactions that produce the dipeptide beta-alanyl-L-histidine (carnosine).
• Carnosine biosynthesis in vertebrates is primarily catalyzed by carnosine synthase (CARNS1), which ligates beta-alanine and L-histidine in an ATP-dependent reaction.
• Carnosine acts as a physiological buffer, antioxidant, and anti-glycation agent, contributing to muscle performance and cellular protection.
• Dysregulation of carnosine metabolism has been linked to ageing, neurological conditions, and metabolic disorders.
• Carnosine shows protective effects in renal ischemia-reperfusion injury by inhibiting GPX4-mediated ferroptosis.
• CRISPR-based models (knockout, knock-in, overexpression) are essential to dissect the causal roles of carnosine biosynthetic enzymes in health and disease.
Description
Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide enriched in skeletal muscle and brain tissue of vertebrates, where it participates in pH buffering, antioxidant defense, and protection against protein glycation. The biosynthetic route leading to carnosine is formally described by the Gene Ontology term GO:0035499, carnosine biosynthetic process, which encompasses the chemical reactions and pathways resulting in the formation of this dipeptide. Understanding this process is fundamental for researchers studying muscle physiology, ageing, and oxidative stress-related diseases. The key enzyme responsible for carnosine synthesis in vertebrates is carnosine synthase (CARNS1), which catalyzes the ATP-dependent ligation of beta-alanine and L-histidine. Beyond CARNS1, the availability of beta-alanine, derived from uracil degradation or dietary sources, and the transport of histidine into cells influence the overall rate of carnosine production. This article integrates the QuickGO definition with published literature to provide a research-grade overview of the carnosine biosynthetic process, its genetic players, and the experimental models used to study it. Researchers can leverage this information to design CRISPR-based experiments that probe the function of carnosine biosynthetic genes in physiological and pathological contexts.
carnosine biosynthetic process At A Glance
| GO ID | GO:0035499 |
|---|---|
| GO term | carnosine biosynthetic process |
| Ontology | biological_process |
| Synonym | carnosine anabolism, carnosine biosynthesis, carnosine formation, carnosine synthesis |
| Major function | Production of the dipeptide carnosine (beta-alanyl-L-histidine) from beta-alanine and L-histidine |
| Key enzyme | Carnosine synthase (CARNS1) in vertebrates |
| Substrates | Beta-alanine and L-histidine |
| Cofactors | ATP (for the ligation reaction) |
| Related pathways | Beta-alanine metabolism, histidine metabolism |
What Is GO:0035499?
GO:0035499 carnosine biosynthetic process is defined as the chemical reactions and pathways resulting in the formation of the dipeptide beta-alanyl-L-histidine (carnosine). This biological process includes the enzymatic steps that generate carnosine from its precursor amino acids, beta-alanine and L-histidine, as well as the regulatory mechanisms that control flux through this pathway.
Why Is carnosine biosynthetic process Important in Cell Biology?
The carnosine biosynthetic process is critical because carnosine itself serves multiple cytoprotective roles, including pH buffering, antioxidant activity, and inhibition of protein glycation, which are relevant to muscle function, ageing, and various diseases. Dysregulation of carnosine metabolism has been observed in disease progression, making the biosynthetic pathway a potential target for therapeutic intervention. Moreover, carnosine has been shown to attenuate renal ischemia-reperfusion injury by inhibiting GPX4-mediated ferroptosis, highlighting its clinical relevance.
• Carnosine biosynthesis provides the dipeptide carnosine, which buffers intracellular pH in skeletal muscle.
• Carnosine acts as an antioxidant and anti-glycation agent, protecting proteins from oxidative damage.
• Altered carnosine metabolism is associated with ageing processes and age-related diseases.
• Dysregulation of carnosine metabolism occurs in the progression of various diseases, including neurological disorders.
• Carnosine protects against renal ischemia-reperfusion injury by inhibiting ferroptosis.
• Carnosine has been investigated for its protective effects in autism spectrum disorders linked to oxidative stress.
• Carnosine biosynthesis is relevant to exercise performance and muscle health.
• The pathway is a target for nutritional and pharmacological interventions aimed at boosting carnosine levels.
What Happens During carnosine biosynthetic process?
Substrate Availability and Uptake
In simple terms: The body must have enough of the two building blocks, beta-alanine and histidine, to make carnosine.
The biosynthesis of carnosine requires the availability of its precursor amino acids, beta-alanine and L-histidine. Beta-alanine is obtained from the degradation of uracil and from dietary sources, while L-histidine is an essential amino acid that must be transported into cells. The intracellular concentrations of these substrates can limit the rate of carnosine synthesis, making their transport and metabolism critical regulatory points.
Enzymatic Ligation by Carnosine Synthase
In simple terms: An enzyme called carnosine synthase joins the two building blocks together to form carnosine.
In vertebrates, carnosine synthase (CARNS1) catalyzes the ATP-dependent ligation of beta-alanine and L-histidine to form carnosine. This enzyme belongs to the ATP-grasp family and utilizes ATP to activate beta-alanine, facilitating the formation of a peptide bond with L-histidine. The reaction releases AMP and pyrophosphate as byproducts.
Regulation of Enzyme Expression
In simple terms: The amount of carnosine synthase enzyme in cells can go up or down, affecting how much carnosine is made.
The expression of CARNS1 is regulated at the transcriptional level, and its activity can be modulated by post-translational modifications. Factors such as muscle fiber type, exercise, and nutritional status influence CARNS1 expression and thus carnosine biosynthesis. Additionally, the availability of beta-alanine is a key determinant of carnosine content in muscle, as supplementation with beta-alanine increases carnosine levels.
Carnosine Degradation and Turnover
In simple terms: Carnosine is constantly broken down and remade, so its levels depend on both synthesis and degradation.
Carnosine is degraded by carnosinase enzymes (CN1 and CN2) into beta-alanine and L-histidine. The balance between synthesis by CARNS1 and degradation by carnosinases determines the steady-state carnosine concentration in tissues. This turnover is important for maintaining physiological carnosine levels and responding to metabolic demands.
Transport and Distribution
In simple terms: After being made, carnosine is moved to different parts of the body where it is needed.
Carnosine is transported across cell membranes by specific transporters, such as the peptide transporter PEPT1 and PEPT2. These transporters facilitate the uptake of carnosine from the diet and its distribution to tissues like skeletal muscle and brain. The expression of these transporters can influence the overall bioavailability of carnosine.
Key Genes Involved in GO:0035499 carnosine biosynthetic process
The following genes and proteins are directly involved in or regulate the carnosine biosynthetic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CARNS1 | Carnosine synthase; catalyzes ATP-dependent ligation of beta-alanine and L-histidine to form carnosine | Primary enzyme for carnosine biosynthesis; knockout models show reduced carnosine levels |
| CNDP1 | Carnosinase 1; degrades carnosine into beta-alanine and L-histidine | Regulates carnosine turnover; polymorphisms linked to diabetic nephropathy |
| CNDP2 | Carnosinase 2; cytosolic enzyme that degrades carnosine | Affects intracellular carnosine levels; potential role in cancer metabolism |
| SLC15A1 | Peptide transporter PEPT1; mediates uptake of carnosine and beta-alanine | Influences dietary carnosine absorption; target for enhancing bioavailability |
| SLC15A2 | Peptide transporter PEPT2; high-affinity transporter for carnosine in kidney and brain | Regulates carnosine reabsorption and distribution |
| SLC36A1 | Proton-coupled amino acid transporter PAT1; transports beta-alanine | May affect substrate availability for carnosine synthesis |
| SLC6A6 | Taurine transporter; also transports beta-alanine | Contributes to beta-alanine uptake in muscle |
| GAD1 | Glutamate decarboxylase 1; involved in GABA synthesis, indirectly affects beta-alanine | May influence beta-alanine pool via GABA shunt |
| GAD2 | Glutamate decarboxylase 2; similar to GAD1 | Potential modifier of beta-alanine availability |
| ALDH9A1 | Aldehyde dehydrogenase 9 family member A1; involved in beta-alanine synthesis from polyamines | Contributes to beta-alanine production |
| AGMAT | Agmatinase; produces putrescine, a precursor for beta-alanine | Links polyamine metabolism to carnosine synthesis |
| ODC1 | Ornithine decarboxylase; produces putrescine | Indirectly affects beta-alanine supply |
| SMOX | Spermine oxidase; produces putrescine and hydrogen peroxide | May influence beta-alanine pool |
| PAOX | Peroxisomal N1-acetyl-spermine/spermidine oxidase; produces putrescine | Contributes to beta-alanine synthesis |
| SAT1 | Spermidine/spermine N1-acetyltransferase; regulates polyamine levels | Indirectly affects beta-alanine availability |
| HIST1H1C | Histone H1.2; not directly involved but histidine metabolism is linked | Histidine supply for carnosine synthesis |
| HAL | Histidine ammonia-lyase; degrades histidine | May compete with carnosine synthesis for histidine |
| HGD | Homogentisate 1,2-dioxygenase; not directly related | No direct role in carnosine biosynthesis |
How Is carnosine biosynthetic process Regulated?
The carnosine biosynthetic process is regulated at multiple levels. The expression and activity of carnosine synthase (CARNS1) are influenced by muscle fiber type, exercise, and nutritional status, with beta-alanine availability being a key limiting factor. Additionally, the balance between synthesis by CARNS1 and degradation by carnosinases (CNDP1 and CNDP2) controls steady-state carnosine levels. Hormonal and metabolic factors, such as insulin and IGF-1, may also modulate carnosine synthesis, although the exact mechanisms require further investigation.
carnosine biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CARNS1 | Reduced carnosine synthesis; muscle weakness, ageing | CARNS1 knockout mouse or C2C12 myoblasts |
| CNDP1 | Diabetic nephropathy; altered carnosine degradation | CNDP1 knockout or overexpression in kidney cells |
| CNDP2 | Cancer metabolism; cytosolic carnosine turnover | CNDP2 knockout in cancer cell lines |
| SLC15A1 | Impaired intestinal absorption of carnosine | SLC15A1 knockout intestinal epithelial cells |
| SLC15A2 | Kidney and brain carnosine transport defects | SLC15A2 knockout mice |
Carnosine Biosynthesis in Ageing and Neurodegeneration
Ageing is associated with a decline in carnosine levels, which may contribute to increased oxidative stress and protein glycation. Carnosine has been proposed as a protective agent against age-related neurodegeneration due to its antioxidant and anti-glycation properties. Dysregulation of carnosine metabolism has been observed in the progression of diseases, including neurological disorders. In autism, oxidative stress is a prominent feature, and carnosine's antioxidant role may be relevant.
Carnosine and Renal Ischemia-Reperfusion Injury
Carnosine attenuates renal ischemia-reperfusion injury by inhibiting GPX4-mediated ferroptosis, suggesting that the carnosine biosynthetic pathway could be targeted to protect kidneys from ischemic damage. This protective effect highlights the therapeutic potential of modulating carnosine levels in renal diseases.
Carnosine in Skin Photoprotection
A biomimetic liposomal co-delivery of quercetin and carnosine enhanced transdermal penetration and provided NRF2/HES1-mediated antioxidant photoprotection, indicating that carnosine biosynthesis and supplementation may be beneficial in dermatological applications.
Carnosine Metabolism in Disease Progression
Dysregulation of carnosine metabolism has been linked to the progression of various diseases, including diabetes, cancer, and cardiovascular disorders. The mechanisms involve altered expression of carnosine synthases and carnosinases, affecting carnosine availability and its protective functions.
From carnosine biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CARNS1 knockout reduce carnosine levels and affect muscle function? | CARNS1 knockout mouse or C2C12 myotubes |
| What is the effect of a point mutation in CARNS1 on enzyme activity? | CRISPR point-mutation knock-in in HEK293 cells |
| Can overexpression of CARNS1 increase carnosine content and protect against oxidative stress? | CARNS1 overexpression in neuronal or muscle cell lines |
| How does tagged CARNS1 localize within cells? | Knock-in of fluorescent tag (e.g., GFP) at CARNS1 locus |
| What is the impact of CNDP1 knockout on carnosine half-life? | CNDP1 knockout in liver or kidney cells |
| Does SLC15A1 knockout alter dietary carnosine absorption? | SLC15A1 knockout intestinal organoids |
How to Study the carnosine biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Carnosine, beta-alanine, histidine concentrations | Quantifying pathway metabolites in cells and tissues |
| Enzyme activity assay | Carnosine synthase activity | Assessing CARNS1 function and mutant effects |
| CRISPR knockout | Gene function loss | Determining necessity of CARNS1 in carnosine synthesis |
| CRISPR knock-in | Tagged protein localization | Visualizing CARNS1 subcellular distribution |
| RNA-seq | Transcriptional changes | Identifying regulators of carnosine metabolism |
| Proteomics | Protein expression and modifications | Detecting post-translational regulation of CARNS1 |
| Immunofluorescence | Protein localization | Confirming cellular distribution of carnosine synthases |
| Metabolic flux analysis | Rate of carnosine synthesis | Measuring pathway activity under different conditions |
CRISPR-Cas9 Genome Editing for Functional Studies
CRISPR-Cas9 knockout of CARNS1, CNDP1, CNDP2, and transporters can elucidate their roles in carnosine biosynthesis and degradation. Point mutations can be introduced to study enzyme kinetics, while knock-in of tags allows visualization of protein localization.
Metabolomics and Mass Spectrometry
Quantification of carnosine and its precursors beta-alanine and histidine using LC-MS/MS enables assessment of pathway flux in cells and tissues. This method is essential for validating the impact of genetic modifications on carnosine levels.
Enzyme Activity Assays
Carnosine synthase activity can be measured in cell lysates using radiolabeled substrates or HPLC-based detection of carnosine formation. These assays help determine the functional consequences of mutations in CARNS1.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in expression of genes involved in carnosine metabolism under different conditions, such as exercise or disease. These approaches identify regulatory networks controlling carnosine biosynthesis.
How CRISPR Can Be Used to Study GO:0035499 carnosine biosynthetic process
Knockout
CRISPR-Cas9 knockout of CARNS1 in cell lines or animal models results in loss of carnosine synthesis, providing a direct test of its necessity. Knockout of CNDP1 or CNDP2 increases carnosine half-life, revealing degradation control.
Point Mutation
Introducing point mutations in the catalytic domain of CARNS1 via CRISPR can dissect the enzymatic mechanism and identify residues critical for substrate binding or catalysis. Such models help correlate genotype with carnosine levels.
Knock-in
Knock-in of a fluorescent tag (e.g., GFP) at the endogenous CARNS1 locus allows real-time tracking of enzyme localization and dynamics in living cells. This approach is valuable for understanding how carnosine synthesis is spatially organized.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression of CARNS1 can boost carnosine production, enabling studies on the protective effects of elevated carnosine in oxidative stress or disease models.
How EDITGENE Supports carnosine biosynthetic process Research
Researchers studying carnosine biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in carnosine production, how mutations affect enzyme function, and whether modulating its expression alters disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for carnosine biosynthetic process research.
Frequently Asked Questions About carnosine biosynthetic process
What is GO:0035499 carnosine biosynthetic process?
GO:0035499 is a Gene Ontology term describing the chemical reactions and pathways that produce the dipeptide carnosine (beta-alanyl-L-histidine).
What genes are involved in carnosine biosynthetic process?
Key genes include CARNS1 (carnosine synthase), CNDP1 and CNDP2 (carnosinases), and transporters such as SLC15A1 and SLC15A2.
Which enzyme catalyzes carnosine biosynthesis?
Carnosine synthase (CARNS1) catalyzes the ATP-dependent ligation of beta-alanine and L-histidine to form carnosine in vertebrates.
What are the substrates for carnosine synthesis?
The substrates are beta-alanine and L-histidine.
How is carnosine biosynthetic process regulated?
It is regulated by substrate availability, CARNS1 expression, and degradation by carnosinases, with beta-alanine being a limiting factor.
What diseases are linked to carnosine metabolism?
Dysregulation of carnosine metabolism is associated with ageing, neurological disorders, diabetes, and renal ischemia-reperfusion injury.
Can carnosine protect against oxidative stress?
Yes, carnosine acts as an antioxidant and anti-glycation agent, protecting cells from oxidative damage.
How can I study carnosine biosynthetic process using CRISPR?
CRISPR knockout, knock-in, and overexpression of CARNS1 and related genes can be used to dissect the pathway and its physiological roles.
What is the role of beta-alanine in carnosine synthesis?
Beta-alanine is a rate-limiting substrate; its availability determines carnosine content in muscle, and supplementation increases carnosine levels.
What model systems are used to study carnosine biosynthesis?
Common models include C2C12 myoblasts, HEK293 cells, and knockout mice for CARNS1, CNDP1, and CNDP2.
Conclusion
The carnosine biosynthetic process (GO:0035499) is a fundamental metabolic pathway that produces the multifunctional dipeptide carnosine, with critical roles in pH buffering, antioxidant defense, and anti-glycation. Dysregulation of this pathway is implicated in ageing, neurological disorders, and renal injury, making it a compelling target for therapeutic intervention. CRISPR-based models are indispensable for dissecting the genetic and molecular mechanisms controlling carnosine synthesis. EDITGENE offers a full range of services to support researchers in this field, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Wang H et al.. 2023. Carnosine attenuates renal ischemia-reperfusion injury by inhibiting GPX4-mediated ferroptosis.. Int Immunopharmacol 124(Pt A):110850 PMID: 37633236
- 2. Xia X et al.. 2025. Biomimetic liposomal co-delivery of quercetin and carnosine for enhanced transdermal penetration and NRF2/HES1-mediated antioxidant photoprotection.. Sci Rep 15(1):44909 PMID: 41462551
- 3. Hipkiss AR et al.. 2002. Reaction of carnosine with aged proteins: another protective process?. Ann N Y Acad Sci 959:285-94 PMID: 11976203
- 4. Hipkiss AR et al.. 2016. Carnosine and the processes of ageing.. Maturitas 93:28-33 PMID: 27344459
- 5. Bozko M et al.. 2020. Dysregulation of Carnosine Metabolism in Progression of Diseases.. Curr Med Chem 27(11):1713 PMID: 32340600
- 6. McGinnis WR. 2004. Oxidative stress in autism.. Altern Ther Health Med 10(6):22-36; quiz 37, 92 PMID: 15624347
- 7. Kwiatkowski S et al.. 2018. Biosynthesis of Carnosine and Related Dipeptides in Vertebrates.. Curr Protein Pept Sci 19(8):771-789 PMID: 29484990
- 8. Sale C et al.. 2013. Carnosine: from exercise performance to health.. Amino Acids 44(6):1477-91 PMID: 23479117
